☆
4.7
Article
Evaluation of surufatinib, an orally available VEGFR, FGFR1 and CSF-1R inhibitor, in combination with immune checkpoint blockade or chemotherapy in preclinical tumor models
EUROPEAN JOURNAL OF CANCER (2020)
Export Citation
Share Paper
Rate this paper
The primary rating indicates the level of overall quality for the paper. Secondary ratings independently reflect strengths or weaknesses of the paper.
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started